anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Kenalog
Trial phase: Phase 2
SMILES: CC1(C)OC2CC3C4CCC5=CC(=O)C=CC5(C)C4(F)C(O)CC3(C)C2(C(=O)CO)O1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 12
Group description: Commercially available triamcinolone acetonide, two 1 mL intra-articular injection

TAcs: Immediate Release Steroid
Eligibility criteria:
Inclusion Criteria:

Written consent to participate in the study
Male or female greater than or equal to 40 years of age
Symptoms consistent with OA in both knees for greater than or equal to 6 months prior to Screening (patient reported is acceptable)
Currently meets ACR Criteria (clinical and radiological) for OA in both knees
Knee pain in both knees for greater than 15 days over the last month (as reported by the patient)
Body mass index (BMI) less than or equal to 40 kg/m2
Morning serum cortisol result within normal range at Screening (5-23 mcg/dL or 138-635 nmol/dL)
Ambulatory and in good general health
Willing and able to comply with the study procedures and visit schedules and able to follow verbal and written instructions.
Willing to abstain from use of protocol-restricted medications during the study

Exclusion Criteria:

Reactive arthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, or arthritis associated with inflammatory bowel disease
History of infection in either knee joint
Clinical signs and symptoms of active knee infection or crystal disease in either knee within 1 month of Screening
Unstable joint (such as a torn anterior cruciate ligament) in either knee within 12 months of Screening
Presence of surgical hardware or other foreign body in either knee
Surgery or arthroscopy of either knee within 12 months of Screening
IA treatment of any joint with any of the following agents within six (6) months of Screening: any corticosteroid preparation (investigational or marketed, including FX006), any biologic agent (e.g., platelet rich plasma (PRP) injection, stem cells, prolotherapy, amniotic fluid injection; investigational or marketed).
IA treatment in either knee with hyaluronic acid (investigational or marketed) within 6 months of Screening
Parenteral or oral corticosteroids (investigational or marketed) within 3 months of Screening
Inhaled, intranasal or topical corticosteroids (investigational or marketed) within 2 weeks of Screening
Females who are pregnant or nursing or plan to become pregnant during the study; men who plan to conceive during the study
Intervention: SODIUM CHLORIDE
Trial phase: Not Applicable
ATC code: A12CA01 | B05CB01 | B05XA03 | S01XA03
SMILES: [Cl-].[Na+]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 22
Group description: Patients who are randomized to the placebo group will receive an injection of 7cc of sterile saline in the affected knee.

Saline: Sterile saline injection will act as a placebo group.
Eligibility criteria:
Inclusion Criteria:

Age of eighteen or older
Diagnosis of symptomatic knee osteoarthritis
Radiographic evidence of knee osteoarthritis. Note: For the purposes of this study, radiographic evidence of knee osteoarthritis is defined as any one or more of the following: osteophytes, joint space narrowing, loss of articular cartilage thickness, subchondral sclerosis or cysts.

Exclusion Criteria:

History of treatment with any intra-articular knee injection
Current ligament instability as demonstrated by a positive Lachman Test, Anterior or Posterior Drawer Test, or positive Valgus or Varus Stress Test.
Known allergy to lidocaine
Under 18 years of age
Pregnant women
Prisoners
Intervention: Betamethasone Sodium Phosphate
Trial phase: Not Applicable
SMILES: CC1CC2C3CCC4=CC(=O)C=CC4(C)C3(F)C(O)CC2(C)C1(O)C(=O)COP(=O)([O-])[O-].[Na+].[Na+]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 23
Group description: Patients who are randomized to the corticosteroid group will receive an injection of 2cc (80mg) of triamcinalone acetonide injectable suspension mixed with 5 cc of 1% plain lidocaine for a total of 7cc of fluid injected in the affected knee.

Corticosteroid injection: Cortisone is a standard of care injection to reduce joint inflammation.
Eligibility criteria:
Inclusion Criteria:

Age of eighteen or older
Diagnosis of symptomatic knee osteoarthritis
Radiographic evidence of knee osteoarthritis. Note: For the purposes of this study, radiographic evidence of knee osteoarthritis is defined as any one or more of the following: osteophytes, joint space narrowing, loss of articular cartilage thickness, subchondral sclerosis or cysts.

Exclusion Criteria:

History of treatment with any intra-articular knee injection
Current ligament instability as demonstrated by a positive Lachman Test, Anterior or Posterior Drawer Test, or positive Valgus or Varus Stress Test.
Known allergy to lidocaine
Under 18 years of age
Pregnant women
Prisoners
Intervention: Rilematovir
Trial phase: Phase 2
SMILES: CS(=O)(=O)CCCn1c(Cn2c(=O)n(CC(F)(F)F)c3ccncc32)cc2cc(Cl)ccc21
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 24
Group description: Participants received JNJ-53718678 500 milligrams (mg) as an oral solution once daily for 7 days.
Eligibility criteria:
Inclusion Criteria:

Participants must have an acute respiratory illness with signs and symptoms consistent with a viral infection (example, fever, cough, nasal congestion, runny nose, sore throat, myalgia, lethargy, shortness of breath, or wheezing) with onset less than or equal to 5 days from the anticipated time of randomization. Onset of symptoms is defined as the time the participant becomes aware of the first sign and/or symptom consistent with a viral infection
Participant has been diagnosed with respiratory syncytial virus (RSV) infection using a rapid polymerase chain reaction (PCR) based or rapid-antigen-detection test
Before randomization, a woman must be not of childbearing potential defined as: Premenarchal, Postmenopausal or Permanently sterile
A male participant must agree to the use of acceptable contraceptive measures
With the exception of the RSV-related illness the participant must be medically stable on the basis of physical examination, medical history, vital signs, and electrocardiogram (ECG) performed at screening

Exclusion Criteria:

Hospitalized participants or participants expected to be hospitalized within 24 hours of screening
History of or concurrent illness (beyond a comorbid condition) that in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the participant or that could prevent, limit, or confound the protocol-specified assessments
Participants who had major surgery within the 28 days prior to randomization or have planned major surgery through the course of the study
Participants who are considered by the investigator to be immunocompromised within the past 12 months
Participant has known or suspected chronic or acute hepatitis B or C infection
Women who are pregnant or breastfeeding
Participants with clinically significant abnormal ECG findings (other than QT-interval corrected for heart rate according to Fridericia [QTcF] interval greater than [>] 500 millisecond [ms]) not consistent with the underlying condition in the study population, as judged by the investigator
Intervention: Mechlorethamine hydrochloride
Trial phase: Phase 2
SMILES: CN(CCCl)CCCl.Cl
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 28
Group description: 0.016% w/w topical mechlorethamine gel applied over a minimum of 8 cm2, nightly, over a period of 4 months.

Valchlor 0.016 % Topical Gel: Apply valchlor nightly on select lesions.
Eligibility criteria:
Inclusion Criteria:

Be eligible to receive Valchlor therapy.
Be at least of 18 years of age and ability to give informed consent
Have stage IA or IB CTCL
Subjects with histologic variants of Mycosis Fungoides such as folliculotropic, granulomatous slack skin, syringotropic MF, or large cell transformation ARE eligible.
A skin biopsy within the last 60 days before start of treatment. In cases with equivocal histological features, the diagnosis may be confirmed with clinicopathologic and/or genetic testing consistent with the National Comprehensive Cancer Network guidelines for Mycosis Fungoides. If sufficient tissue is not available to perform genetic testing, a new biopsy will be performed even if the subject has had a biopsy within 60 days of start of treatment.
Females of child bearing potential must agree to use two highly effective methods of contraception (strongly recommended that one of the two forms of contraception be non-hormonal such as condom plus spermicide, condom plus diaphragm with spermicide, or have a vasectomized partner) or use an intrauterine device until 30 days after the last day of drug administration. Perimenopausal women must be amenorrhoeic for at least 12 months to be considered of nonchildbearing potential.
Males with female partners of child bearing potential must agree to sexual abstinence or use two reliable forms of effective contraception simultaneously (strongly recommended that one of the two forms should be non-hormonal as described above) during the entire treatment period and 30 days after the last dose.
Must be able to comply with the study instructions, apply the study medication as directed, and attend all visits.
Willingness to avoid sun exposure and ultraviolet B light in areas to be treated.

Exclusion Criteria:

Have been treated with topical mechlorethamine within 6 months in lesions followed during this study.
Have received any topical therapy directed against MF within 2 weeks of start of treatment in areas intended to be treated in this study.
Have received any systemic therapy (oral or injectables) within 3 weeks of start of treatment.
Not have any intercurrent illness or infection that would interfere with study participation
Known hypersensitivity to mechlorethamine or triamcinolone.
Breastfeeding, pregnancy, or intention to become pregnant.
Intervention: Cholecalciferol
Trial phase: Phase 4
ATC code: A11CC05 | A11CC55 | M05BB03 | M05BB04 | M05BB05 | M05BB07 | M05BB08 | M05BB09 | M05BX53
SMILES: [H][C@@]12CC[C@]([H])([C@H](C)CCCC(C)C)[C@@]1(C)CCC/C2=C\C=C1\C[C@@H](O)CCC1=C
Sex: Female
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 5
Group description: Cholecalciferol 5,000 IU PO daily

Vitamin D: Oral medication daily
Eligibility criteria:
Inclusion Criteria:

Polycystic Ovary Syndrome diagnosis (Rotterdam Criteria)
Vitamin D insufficiency (serum Vitamin D <30 ng/mL)
Insulin resistance
Mild or greater severity of depression by Beck Depression Inventory-II

Exclusion Criteria:

Current metformin use
Vitamin D supplementation of > 50,000 IU following confirmation of Vitamin D insufficiency
Insulin-dependent diabetes mellitus
Pregnancy or breastfeeding
Untreated hypothyroidism
Current active substance abuse
Other major medical comorbidity: renal or hepatic dysfunction, severe pulmonary
Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data
Intervention: Oxymetazoline Hydrochloride
Trial phase: Phase 4
SMILES: Cc1cc(C(C)(C)C)c(O)c(C)c1CC1=NCCN1.Cl
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 46
Group description: Participants will receive energy-based therapy (Potassium Titanyl Phosphate [KTP], Pulsed Dye Laser [PDL], or Intense Pulsed Light [IPL]) plus once daily application of oxymetazoline hydrochloride (HCl) cream 1.0%.

Oxymetazoline HCL 1.0% Cream: Oxymetazoline HCl cream 1.0% once daily application

Energy-Based Therapy: Energy-based therapies (Potassium Titanyl Phosphate [KTP], Pulsed Dye Laser [PDL], or Intense Pulsed Light [IPL])
Eligibility criteria:
Inclusion Criteria:

-Documented clinical diagnosis of rosacea.

Exclusion Criteria:

History of any of the following conditions: Raynaud's syndrome, narrow angle glaucoma, orthostatic hypotension, cerebral or coronary insufficiency, thromboangiitis obliterans, scleroderma, Sjögren's syndrome, severe or unstable or uncontrolled cardiovascular disease, or any other current uncontrolled systemic disease
Diagnosis or presence of any of the following conditions: rosaceaconglobata, rosacea fulminans, isolated rhinophyma, isolated pustulosis of the chin, peri-oral dermatitis, demodicidosis, facial keratosis pilaris, seborrheic dermatitis, acute lupus erythematosus, or chronic recurring facial acne
Current treatment with monoamine oxidase (MAO) inhibitors
Current treatment with niacin ≥ 500 mg/day
Greater than 3 inflammatory lesions on the face
History or current evidence of drug or alcohol abuse within 12 months prior to the screening visit.
Intervention: Clopidogrel
Trial phase: Phase 2 | Phase 3
ATC code: B01AC04
SMILES: [H][C@@](C(=O)OC)(c1ccccc1Cl)N1CCc2sccc2C1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 3043
Group description: To observe the efficacy and safety of clopidogrel 75mg qdpo. in patients with coronary artery disease.

clopidogrel: clopidogrel 75 mg once daily for 5 consecutive days at least.
Eligibility criteria:
Inclusion Criteria:

Patients with coronary artery disease

Exclusion Criteria:

younger than 18 years of age;
anti-platelet therapy with clopidogrel or ticagrelor for less than 5 days;
previous or current treatment with any other potentially confounding drugs.
Intervention: Ticagrelor
Trial phase: Phase 2 | Phase 3
ATC code: B01AC24
SMILES: CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 3043
Group description: To observe the efficacy and safety of ticagrelor 90mg bidpo. in patients with coronary artery disease.

ticagrelor: ticagrelor 90 mg twice daily for 5 consecutive days at least.
Eligibility criteria:
Inclusion Criteria:

Patients with coronary artery disease

Exclusion Criteria:

younger than 18 years of age;
anti-platelet therapy with clopidogrel or ticagrelor for less than 5 days;
previous or current treatment with any other potentially confounding drugs.
Intervention: Ticagrelor
Trial phase: Phase 2 | Phase 3
ATC code: B01AC24
SMILES: CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 3043
Group description: To observe the efficacy and safety of ticagrelor 45mg bidpo. in patients with coronary artery disease.

Ticagrelor: ticagrelor 45 mg twice daily for 5 consecutive days at least.
Eligibility criteria:
Inclusion Criteria:

Patients with coronary artery disease

Exclusion Criteria:

younger than 18 years of age;
anti-platelet therapy with clopidogrel or ticagrelor for less than 5 days;
previous or current treatment with any other potentially confounding drugs.
Intervention: Ticagrelor
Trial phase: Phase 2 | Phase 3
ATC code: B01AC24
SMILES: CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 3043
Group description: To observe the efficacy and safety of ticagrelor 90mg qdpo. in patients with coronary artery disease.

ticagrelor: ticagrelor 90 mg once daily for 5 consecutive days at least.
Eligibility criteria:
Inclusion Criteria:

Patients with coronary artery disease

Exclusion Criteria:

younger than 18 years of age;
anti-platelet therapy with clopidogrel or ticagrelor for less than 5 days;
previous or current treatment with any other potentially confounding drugs.
Intervention: Defibrotide
Trial phase: Phase 2
ATC code: B01AX01
SMILES: CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3c(ccn3C)c2)c(O)cc1OP(=O)(O)O
Sex: All
Age groups: Child | Adult
Healthy volunteers: No
Participants at risk: 25
Group description: 6.25mg/kg administered intravenously every 6 hours for 28 to 35 days, starting on the day before conditioning is initiated.

Defibrotide: Defibrotide is an anticoagulant and fibrinolytic agent that has been shown to be an effective treatment in other endothelial disorders such as hepatic veno-occlusive disease.
Eligibility criteria:
Inclusion Criteria

Age 0-30 years of age
Life expectancy > 6 months
Eastern Cooperative Oncology Group or Karnofsky Performance Status >40
Meets minimum organ function requirements per institutional standard of care guiding clearance for autologous or allogeneic stem cell transplantation.
Patients must meet TMA High-Risk criteria 5A or 5B below:

5A. Patients undergoing tandem autologous transplant with thiotepa in one or more of the conditioning regimens

OR:

5B. . Patients with at least 3 of the following characteristics:

>10 years of age
Non-Caucasian race/ Hispanic ethnicity
Undergoing haploidentical transplant
Minor ABO blood group mismatch

Exclusion Criteria:

Age >30 years
Life expectancy < 6 months
Known bleeding diathesis or bleeding risk deemed by the treating physician to be a contraindication to administration of anticoagulants.
Known hypersensitivity reaction to defibrotide
Any patient not meeting TMA High-Risk criteria
Pregnant women are excluded from this study because they will be receiving teratogenic therapy as part of the stem cell transplant.
Intervention: Sotagliflozin
Trial phase: Phase 3
ATC code: A10BK06
SMILES: CCOc1ccc(Cc2cc([C@@H]3O[C@H](SC)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 125
Group description: Following a 2 week run-in period, participants were randomized to Sotagliflozin 400 mg administered as two 200 mg sotagliflozin tablets, once daily, before the first meal of the day, for up to 26 weeks in the Core Treatment Period. Participants were eligible to continue treatment in the Extension Period. The total treatment duration was planned for up to 104 weeks.
Eligibility criteria:
Inclusion criteria :

Participants with T2D managed with diet and exercise only or with a stable antidiabetes regimen (in monotherapy or combination therapy that can include oral antidiabetes medications, insulin, or glucagon-like peptide-1 agonists) for more than 12 weeks.
Participants has given written informed consent to participate in the study in accordance with local regulations.

Exclusion criteria:

Age <55 years.
Women who have been postmenopausal (or undergone bilateral oophorectomy) for less than 5 years.
Type 1 diabetes mellitus.
Body mass index (BMI) ≤20 or >45 kilogram per meter square kg/m^2 or bodyweight that exceeds the weight limits of the DXA scanner.
Hemoglobin A1C (HbA1c) <7.0% or HbA1c >11.0%.
Use of a selective sodium-glucose cotransporter type 2 (SGLT2) inhibitor or thiazolidinedione within 24 months.
Bone mineral density (BMD) T- score <-2.0 at any site (ie, lumbar spine, total hip, or femoral neck).
History of fracture within 12 months (except for fractures of the hand/fingers, foot/toes, facial bones, and skull).
Treatment with medications known to affect bone mass or modify the risk of fractures within 36 months (eg, bisphosphonates, selective estrogen receptor modulators, calcitonin, teriparatide, denosumab, strontium ranelate, growth hormone, aromatase inhibitors, androgen deprivation therapy, carbamazepine, phenytoin, and phenobarbital). Use of hormonal replacement that includes systemic or transdermal estrogen or testosterone is excluded unless is stable for at least 24 months prior to Screening.
Lower extremity complications (such as skin ulcers, infection, osteomyelitis and gangrene) identified during the Screening period, and still requiring treatment at randomization.
Uncontrolled high blood pressure, severe anemia, severe cardiovascular problems, such as heart failure, active cancer, or other conditions that the Investigator believes with result in a short life expectancy.
Renal disease as defined by an estimated glomerular filtration rate (eGFR) <30 milliliter per minute (mL/min)/1.73 meter square (m^2) at the Screening Visit by the 4 variable Modification of Diet in Renal Disease equation.

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Intervention: Tenofovir
Trial phase: Phase 4
SMILES: C[C@H](Cn1cnc2c(N)ncnc21)OCP(=O)(O)O
Sex: All
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 20
Group description: DOT Diary mobile app and Emtricitabine / Tenofovir Disoproxil Oral Tablet

Emtricitabine / Tenofovir Disoproxil Oral Tablet: Open label daily emtricitabine/tenofovir disoproxil oral tablet

DOT Diary mobile app: DOT Diary mobile application for tracking medication adherence and sexual activities.
Eligibility criteria:
Inclusion Criteria:

Self-identifies as a man
Age 18-35 at enrollment

Reports having anal sex with a man or trans woman in the past 12 months and one or more of the following criteria in the past 12 months:

Any condomless anal sex (not in a mutually monogamous relationship with an HIV-negative partner)
Two or more anal sex partners
Self-reported STI (gonorrhea, chlamydia, syphilis)
Having a known HIV-positive sexual partner
HIV-negative as determined by a negative 4th generation HIV test at screening and negative rapid 4th generation test at enrollment
Currently taking PrEP or interested in initiating PrEP

Eligible to take PrEP

Creatinine clearance ≥60 ml/min as estimated by Cockcroft-Gault equation at screening
Hepatitis B surface antigen (HBsAg) negative
Willing and able to provide written informed consent
Able to read and speak English
Smartphone ownership compatible with DOT Diary
Meets local locator requirements

Exclusion Criteria:

Any reactive HIV test at screening or enrollment
Signs or symptoms of acute HIV infection at screening or enrollment
History of pathological bone fracture not related to trauma
Taking nephrotoxic medications
History of participation in the active arm of an HIV vaccine trial
In a mutually monogamous sexual relationship with an HIV-negative partner for the past 12 months
Does not live, work or play in Atlanta Metropolitan Area, San Francisco, Alameda, Marin, Contra Costa, Santa Clara, or San Mateo Counties
Unable to commit to study participation for 8 weeks
Any medical, psychiatric, or social condition or other responsibilities that, in the judgment of the investigator, would make participation in the study unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives.